Most weight care programs stop at the scale. EmblaRestore goes further, using behavioral coaching and low-dose GLP-1s prescribed by independent licensed clinicians to control and reverse the cardiometabolic conditions that drive your highest-cost claims.
Most weight care programs track pounds lost. They don't track HbA1c, blood pressure, or cholesterol. Weight comes down but the conditions that drive your costliest claims go unmonitored and untreated.
If weight loss improves cardiometabolic markers, medication should be reduced. Most programs never revisit the medication stack. Members stay on the same drugs at the same doses, even when their clinical picture has changed.
Without tiered outcomes, lab tracking, and structured reassessment, weight care is a wellness perk. Not a clinical intervention. The ROI stays invisible.
EmblaRestore is a structured cardiometabolic care program. Every member follows a clinical pathway with baseline labs, tiered targets, and active deprescribing. Weight loss is a byproduct. Disease reversal is the goal.
Talk to our teamLow-dose GLP-1 therapy prescribed by independent licensed clinicians, combined with 1:1 behavioral coaching grounded in CBT and ACT. Nutrition, movement, sleep, stress, and emotional health. 16.7% average weight loss over 64 weeks using less than half the standard maximum dose.
Lab monitoring for HbA1c, glucose, blood pressure, and cholesterol. Evidence-based nutrition protocols for diabetes, hypertension, and dyslipidemia. Condition-specific coaching and metabolic education via the Embla app.
Structured GLP-1 tapering beginning at month 16. Goal-setting for broader medication reduction across conditions. Long-term reversal targets. 78.5% of participants successfully tapered or stopped GLP-1s with no average weight regain.
Cohort-level data reported at Month 3, Month 6, and Month 12. HbA1c, blood pressure, lipids, weight, medication changes, and tier progression. You see the clinical and financial impact as it develops.
At enrollment, every member is assigned an outcome tier based on baseline labs. Progress is tracked continuously and confirmed at Month 6.
Lab markers approaching normal range. Condition controlled but still medication-dependent.
50%+ improvement in key cardiometabolic markers from baseline. Medication reduction underway.
Off cardiometabolic medication. Lab markers in healthy range. Full metabolic independence.
The TRIM study is Embla's own published research: 2,694 participants, 64 weeks of real-world clinical data. Published in Diabetes, Obesity and Metabolism (Seier et al., 2025). Weight loss comparable to randomized controlled trials, with less than half the medication used.
Over 64 weeks, across all BMI classes. Real-world outcomes, not a controlled trial population.
Structured tapering built into the program. No indefinite prescribing. No average weight regain post-taper.
~1.08 mg/week average semaglutide, far below the 2.4 mg/week standard maximum. Lower doses mean lower pharmacy spend.
EmblaRestore operates as a true carve-out benefit. No claims feeds. No PBM coordination. No plan amendments. Fully managed by Embla.
We align on your population, clinical goals, and how EmblaRestore fits your benefits strategy or existing care model.
Enrollment materials, member communications, lab coordination, and provider onboarding. All managed by Embla. Live in as little as 7 days.
Members matched with their coach. Baseline labs ordered. Clinical targets set. You receive your first cohort report at Month 3.
Whether you need to reduce cardiometabolic claims, add a clinical layer to your weight care offering, or give your providers a structured behavioral partner between visits, EmblaRestore is built for exactly that.
